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A B S T R A C T
Acute myeloid leukemia (AML) is the predominant acute leukemia among adults, characterized by an
accumulation of malignant immature myeloid precursors. A very promising way to treat AML is
differentiation therapy using either all-trans-retinoic acid (ATRA) or 1,25-dihydroxyvitamin D3 (1,25D), or
the use of both these differentiation-inducing agents. However, the effect of combination treatment
varies in different AML cell lines, and this is due to ATRA either down- or up-regulating transcription of
vitamin D receptor (VDR) in the cells examined. The mechanism of transcriptional regulation of VDR in
response to ATRA has not been fully elucidated. Here, we show that the retinoic acid receptor a (RARa) is
responsible for regulating VDR transcription in AML cells. We have shown that a VDR transcriptional
variant, originating in exon 1a, is regulated by RARa agonists in AML cells. Moreover, in cells with a high
basal level of RARa protein, the VDR gene is transcriptionally repressed as long as RARa agonist is absent.
In these cells down-regulation of the level of RARa leads to increased expression of VDR. We consider that
our ﬁndings provide a mechanistic background to explain the different outcomes from treating AML cell
lines with a combination of ATRA and 1,25D.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Acute myeloid leukemia (AML) is the predominant acute
leukemia among adults. This disease is difﬁcult to treat due to
variable underlying causes and most patients are elderly and often
excluded from aggressive chemotherapy trials [1]. A very attractive
and gentler way to treat patients with AML is so called
differentiation therapy [2,3]. The most successful differentiation
therapy agent is all-trans-retinoic acid (ATRA). This is used
routinely to treat a very rare form of AML called acute
promyelocytic leukemia (APL), in which a PML-RARa fusion
protein is generated by a t(15;17)(q22;q12) chromosomal translo-
cation [4]. However, the success of ATRA-based differentiation
therapy has not been extended to other forms of AML [5]. 1,25-
dihydroxyvitamin D3 (1,25D) is capable of inducing in vitro
differentiation of AML cell lines [6], but was not found to be very
effective in early clinical trials of AML [7]. Previous work has shown* Corresponding author.
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0960-0760/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access articthat a combination of 1,25D and ATRA can produce a synergistic
differentiation effect [8]. However, our recent research has shown
that the effect of this combination treatment varies in AML cell
lines [9]. This is due to either down- or up-regulation of vitamin D
receptor (VDR) transcription in response to ATRA in the AML cell
lines examined. HL60 cells have a high constitutive level of VDR
mRNA and VDR expression is down-regulated by ATRA, whereas
KG1 cells have a very low basal level of VDR mRNA, and ATRA up-
regulates VDR expression [9].
The gene encoding human VDR is located on chromosome 12, it
covers about 100 kb of genomic DNA [10] and its composition is
complex. The gene is composed of 14 exons, and translation of VDR
protein spans from the exon 2 to the exon 9 [11,12]. Due to T to C
polymorphism, which eliminates the most 50-located ATG codon in
the exon 2, translation starts from the second in-frame ATG codon
in some individuals. Thus, two variants of VDR protein exist, one
three amino-acids shorter (424 aa) than the other (427 aa) [13]. The
50 region is very complex, and consists of the six exons 1a-1f, which
together with the corresponding promoter regions are alterna-
tively used in transcription regulation in various tissues [11]. Only
three promoter regions have been identiﬁed in the region thatle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Organization of the human VDR locus and regulation of VDR transcription in response to ATRA in AML cells.
(A) Composition of the 50 regions of VDR are according to Crofts et al. (1998) and Zella et al. (2010), and (B) shows transcripts identiﬁed in our experiments in un-stimulated
and ATRA-stimulated HL60 and KG1 cells. For each type of cell and stimulation, 15–20 individual clones were sequenced (67 altogether) and all the variants identiﬁed are
presented here. Black boxes represent protein coding exons, grey—noncoding exons localized in the regulatory region of the gene. White boxes represent promoter regions.
The hatched box represents the newly identiﬁed exon (1g). The frequencies of the transcripts identiﬁed are given on the left side of their graphical representation.
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from exon 1d are regulated by the promoter upstream to exon 1a,
and exons 1f and 1c have their own upstream promoters (Fig.1(A)).
The regulation of remaining exons remains to be elucidated [11–
13].
Transcripts which originate from exon 1a and 1d are expressed
in most of the 1,25D-responsive tissues, while a transcript
originating in exon 1f is selectively expressed in tissues that play
a role in calcium-phosphate homeostasis [11]. Moreover, it has
been shown that the transcripts starting from exon 1d give rise to a
longer VDR protein, named VDR B1 [11,14]. ATRA-mediated up-
regulation of VDR transcription has been reported in the past.
However, due to the lack of retinoic acid response elements (RARE)
in VDR promoter region, the mechanism of the inﬂuence of ATRA
on VDR transcription remains unclear. Non-classical ATRA-
responsive regions have been reported to be present in a regulatory
element localized downstream of exon 1c (as detected in reporter
assays using transfected HeLa cells) [13] and in the promoter
region upstream of exon 1c (detected in similar assays using breast
cancer cells) [15]. It is thus tempting to speculate that the
mechanism of regulation of VDR by ATRA, and whether the
outcome is up- or down-regulation of VDR expression, are cell-
context dependent.
ATRA is a non-selective agonist of the three distinct isoforms of
retinoic acid receptors (RAR) a, b and g, and these occur as
numerous splicing variants [16–18]. RARs, similarly to VDR, form
heterodimers with retinoid X receptors (RXR) and act as ligand-
regulated transcription factors via binding to speciﬁc RAREs.
However, it should be remembered that un-ligated RARa, and to
much lesser extent RARb and g, may act as transcriptional
repressors to certain genes [19,20]. Due to the differences in the
ligand binding domains of distinct RAR isoforms, it has been
possible to synthesize a number of selective RAR agonists and
antagonists [21]. The means to selectively activate or inhibit
distinct isoforms of RARs have led to discovery of their diverse
functions, which often relate to various aspects of cell differentia-
tion [22].
To gain a better understanding of the molecular mechanisms of
regulation of VDR transcription by RARs in AML cells we have
examined the transcriptional variants produced by these cells. We
have used a rapid ampliﬁcation of cDNA ends (50-RACE) method toinvestigate this problem. The use of selective RAR agonists has
allowed us to identify the isoform of RAR that regulates a
transcriptional variant of VDR in AML cells. Through luciferase
reporter assays, we localized the region in the VDR promoter which
is involved in the regulation of VDR expression in response to ATRA.
Finally, we have addressed the role of un-ligated RARa in AML cells
by using shRNA gene silencing technology.
2. Materials and methods
2.1. Cell lines and cultures
HL60 cells were obtained from the local cell bank at the
Institute of Immunology and Experimental Therapy in Wrocław,
and KG1, U973, MV4-11, MOLM-13 and NB-4 cells were purchased
from the German Resource Center for Biological Material (DSMZ
GmbH, Braunschweig, Germany). The cells were grown in RPMI-
1640 medium with 10% fetal bovine serum (FBS), 100 units/ml
penicillin and 100 mg/ml streptomycin (Sigma, St Louis, MO) and
maintained at standard cell culture conditions.
2.2. Chemicals and antibodies
1,25D was purchased from Cayman Europe (Tallinn, Estonia)
and ATRA was from Sigma. The compounds were dissolved in an
absolute ethanol to 1000 ﬁnal concentrations, and subsequently
diluted in the culture medium to the required concentration.
AGN191183 (pan RAR agonist), AGN195183 (RARa agonist) and
AGN205327 (RARg agonist) have been described previously [23]
and were synthesized at the Shangai Institute of Materia Medica.
Tazarotene (RARbg agonist) [24] and BMS453 (RARb agonist) [25]
were purchased from Tocris Bioscience (Bristol, UK). These
compounds were stored at 10 mM concentrations in 50% metha-
nol/50% dimethylsulphoxide at 20 C and subsequently diluted in
the culture medium to the required concentration. Rabbit
polyclonal anti-RARa (sc-550), anti-actin (sc-1616), anti-Histone
H1 (sc-10806) and mouse monoclonal anti-VDR (sc-13133) anti-
bodies were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Anti-lamin C2 custom made antibody was a kind gift from Prof.
Ryszard Rzepecki (Faculty of Biotechnology; University of
Wrocław). Goat anti-rabbit IgG and a goat anti-mouse IgG
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esearch (West Grove, PA).
2.3. cDNA synthesis and Real-time PCR
Isolation of total RNA, reverse transcription into cDNA and Real-
time PCR reactions were performed as published before [9], using
CFX Real-time PCR System (Bio-Rad Laboratories Inc., CA). The
sequences of VDR, CYP24A1 and GAPDH primers and reaction
conditions were described previously [26]. The RARA, RARB and
RARG primers were obtained from RealTimePrimers.com (Real
Time Primers, LLC, PA). The primers for VDR variants were: forward
for VDR1a: 50GCGGAACAGCTTGTCCACCC, for VDR1d:
50GCTCAGAACTGCTGGAGTGG, for VDR1 g:
50TTGCTCATCCAGCTTCCCAGAC, and reverse for all variants was:
50GAAGTGCTGGCCGCCATTG. Quantiﬁcation of gene expression
was analyzed with either the DCq or DDCq method using GAPDH
as the endogenous control. Primers efﬁciencies were measured in
all cell lines using a Real-time PCR reaction based on the slope of
the standard curve. The results were normalized to primer
efﬁciencies to compare gene expression in different cell lines.
Real-time PCR assays were performed at least in triplicate.
2.4. Flow cytometry
The expression of cell surface markers of differentiation was
determined by ﬂow cytometry. The cells were incubated with
10 nM 1,25D or/and 1 mM ATRA for 96 h, then washed and stained
with 1 ml of ﬂuorescently labeled antibodies CD11b/FITC and CD14/
PE or with the appropriate control immunoglobulins (all from
ImmunoTools; Friesoythe, Germany) for 1 h on ice. Next, they were
washed with ice-cold PBS and suspended in 0.5 ml PBS supple-
mented with 0.1% BSA prior to analysis on FACS Calibur ﬂow
cytometer (Becton Dickinson, San Jose, CA). The acquisition
parameters were set for an isotype control. The experiments were
repeated at least three times and data analysis was performed
using WinMDI 2.8 software (freeware by Joseph Trotter).
2.5. Identiﬁcation of transcriptional start sites of VDR transcripts
To identify the transcriptional start sites of VDR transcripts, 50-
RACE (rapid ampliﬁcation of cDNA ends) was used [27]. Ten mg of
RNA isolated from unstimulated or ATRA-stimulated HL60 and
KG1 cells was digested with calf alkaline phosphatase (CIP, New
England Biolabs) in the presence of RiboLock RNase inhibitor for
1 h at 37 C and puriﬁed by extraction with TRI reagent. Half of the
CIP-digested RNA was treated with tobacco acid pyrophosphatase
(TAP, Epicentre) for 1 h at 37 C in 10 ml reaction mixture
containing TAP buffer, 0.5 U of TAP and 20 U of RiboLock RNase
inhibitor. 2 ml of TAP-treated RNA was ligated with a RNA
oligonucleotide (50-GCUGAUGGCGAUGAAUGAACACUGCGUUUG-
CUGGCUUUGAUGAAA) for 1 h at 37 C in a 10 ml reaction
containing 0.3 mg of the oligonucleotide, 5 U of RNA ligase (New
England Biolabs), RNA ligase buffer and 20 U of RiboLock RNase
inhibitor. Two ml of RNA was then reverse transcribed using
SuperScript III reverse transcriptase (Invitrogen) and random
hexamers or gene-speciﬁc oligonucleotide complementary to exon
2 of VDR gene (50-GCAGCCTTCACAGGTCATAGC). The cDNA was
ampliﬁed in nested PCR reactions (2  20 cycles, annealing temp.
52 C, in the presence of 1.2 M betaine) using primers complemen-
tary to 50-adapter (50-GCTGATGGCGATGAATGAACACTG, 5050-
CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG) and exon 2 of
VDR gene (50-GCAGCCTTCACAGGTCATAGC, 50-GTGAAAGC-
CAGTGGCTCGGT). The ampliﬁcation products were directly cloned
into pGEMT-easy vector. For each type of cell and stimulation 15–
20 individual plasmid clones were sequenced using SP6 primer (50-ATTTAGGTGACACTATAG) and BigDye 3.1 Terminator Cycle Se-
quencing Kit (Life Technologies). In total, 67 clones were
sequenced. The sequencing reaction was analyzed using ABI Prism
310 Genetic Analyzer. The sequences of VDR transcripts obtained
were aligned with the genomic sequence of VDR gene using Spidey
software to identify exons and transcriptional start sites.
2.6. Reporter assays
Two forms of the VDR 1a promoter: 1a long (1935/ + 71) and 1a
short (464/ + 71) were cloned upstream of the ﬁreﬂy luciferase
gene in the pGL3 Basic vector (Promega) using SLIC cloning. First,
promoter fragments were obtained by ampliﬁcation of the
genomic DNA isolated from KG1 cells in a PCR reaction using
Phusion Green High–Fidelity Polymerase (Thermo Scientiﬁc) and
primer pairs: VDRp1aDF-pGL3, VDRp1aR and VDRp1aKF-pGL3,
VDRp1aR-pGL3 for the long and the short form respectively. The
SLIC reaction was performed as following: 0.038 pmol of BglII/
HindIII-digested pGL3Basic, 0.08 pmol of VDR 1a promoter
fragment (long or short form), 1  BSA, 1  NEB buffer 2, 0.5 ml
T4 polymerase were incubated for 2.5 min at room temperature in
a ﬁnal volume of 10 ml. Then 20 ng of RecA protein were added and
the reaction was stored on ice. Chemically competent DH5a cells
were transformed with 5 ml of the reaction product using thermal
shock method (45 s, 42 C).
For the reporter assays, HL60 cells were co-transfected with
2.5 mg of the reporter pGL3 plasmids and with the 1 mg of the
control pRL-TK plasmid, using Neon1Transfection System (Invi-
trogenTM, Carsbad, CA) according to the manufacturer’s manual. At
24 h after transfection, the cells were left untreated or stimulated
for 96 h with 1 mM ATRA. After that time the luciferase activity was
measured with Dual-Glo Luciferase Assay System (Promega Corp.,
Madison, WI) according to the manufacturer’s manual using
EnVision Multilabel Plate Reader (Perkin Elmer, Waltham, MS).
Fireﬂy luciferase activities were determined in three independent
co-transfections and were normalized to the Renilla luciferase
activities of the internal control pRL-TK vector from the same
culture.
2.7. Gene silencing reagents and procedure
The gene silencing was performed using shRNA lentiviral
particles: the RARA shRNA lentiviral particles (sc-29465-V)
containing three target-speciﬁc 19–25nt shRNAs designed to
speciﬁcally knockdown RARA gene expression, and the control
shRNA lentiviral particles (sc-108080) containing scrambled
shRNA sequences which were used as a negative control (both
Santa Cruz Biotechnology, Inc.). KG1 cells were seeded on 24-well
plates (2 104 cells per well) and after 24 h the cells were infected
with 20 ml of lentivirus particles in medium containing 1 mg/ml
polybrene (Santa Cruz Biotechnology, Inc.) for 8 h. The medium
was changed and the cells were grown for two more days. After
that time, the medium was replaced with selection medium
containing 1 mg/ml puromycin (Santa Cruz Biotechnology, Inc.).
2.8. Western blots
In order to obtain cytosolic and nuclear extracts 5 106 cells/
sample were washed and lysed using Pierce NE-PER Nuclear and
Cytoplasmic Extraction Reagents according to the user’s manual.
Lysates were denatured by adding 5 sample buffer (1/4 vol of the
lysate) and boiled for 5 min 25 ml of each lysate were separated in
SDS-PAGE and electroblotted to PVDF membrane. The membranes
were then dried, and incubated sequentially with primary and a
horseradish peroxidase-conjugated secondary antibody. The pro-
tein bands were visualized by chemiluminescence. Then the
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quent antibodies. Western blots were repeated 3 times.
2.9. Statistical analysis
For statistical analysis one-way ANOVA was used to test the null
hypothesis that samples in two or more groups are drawn from
populations with the same mean values. When the ANOVA test had
shown that the null hypothesis is not true, Student’s t-test for
independent samples was used to analyze the differences between
the pairs of groups (Excel, Microsoft Ofﬁce and free ANOVA
Calculator: http://www.danielsoper.com/statcalc3/calc.aspx?
id=43).Fig. 2. Regulation of VDR transcription and cell differentiation in response to ATRA or/
(A) Up-regulation of VDR expression in response to ATRA in KG1 and NB-4 cells and (B) d
1 and U937 cells. The cells were exposed to 1 mM ATRA for the times given on the graphs
expression levels. The bar charts show mean values (SEM) of absolute expression levels
cells are marked with asterisks.
KG1 (C), NB-4 (D), HL60 (E), MOLM-13 (F), NOMO-1 (G) and U937 (H) cells were expose
markers were detected using ﬂow cytometry. The bar charts show the mean percentages
from those obtained for 1,25D-treated cells are marked with ¥, while the values that differ3. Results
3.1. Regulation of VDR in response to ATRA in six AML cell lines
Our previous work has shown that transcription of VDR gene is
regulated in an opposite manner in response to ATRA in two of the
commonly used cell lines that typify AML cells. VDR transcription
was observed to be up-regulated in KG1 cells and down-regulated
in HL60 cells. Here, we have examined the regulatory patterns seen
in additional human AML cell lines. The molecular and cytogenetic
characteristics of the cell lines studied are complex and informa-
tion is provided in Supplementary Table 1. HL60, KG1, U973,
MOLM-13, NB-4 and NOMO-1 cells were exposed for 24, 48, 72 and
96 h to 1 mM ATRA, and the expression of VDR was measured byand 1,25D in AML cells.
own-regulation of VDR expression in response to ATRA in HL60, MOLM-13, NOMO-
 and expression of the VDR gene was measured by Real-time PCR relative to GAPDH
. Values that differ signiﬁcantly (p < 0.05) from those obtained for respective control
d to 10 nM 1,25D or/and to 1 mM ATRA for 96 h and CD11b and CD14 differentiation
 of CD11b and CD14 positive cells (SEM). Values that differ signiﬁcantly (p < 0.05)
 signiﬁcantly (p < 0.05) from those obtained for ATRA-treated cells are marked by .^
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of constitutive expression of VDR was observed in NB-4 cells
(Fig. 2(A)). However, it should be remembered that NB-4 cells
harbor one copy of the PML-RARA fusion gene, which encodes the
fusion protein PML-RARa. Previous studies have shown that PML/
RARa impairs the localization of VDR in the nucleus by binding to
VDR and by this means inhibits its transcriptional activity [28]. VDR
expression was up-regulated by ATRA to a signiﬁcant extent in NB-
4 cells (2.4 times), but to a lesser extent than observed for KG1 cells
(more than 7 times). In contrast, VDR expression was down-
regulated in response to ATRA in HL60 cells (3.2 times), MOLM-13
(2.9 times) and NOMO-1 (5.2 times) cell lines (Fig. 2(B)). The
absolute level of VDR expression was very low in U937 cells, and it
was further down-regulated in response to ATRA (1.8 times),
however, this decrease was not statistically signiﬁcant. Addition-
ally, constitutive VDR expression is about 10 times higher in
HL60 than in KG1 cells.
The differentiating effects of 1,25D or/and ATRA were examined
by ﬂow cytometry. Fig. 2(C)–(H) show that for all the cell lines
studied the combined effect of ATRA and 1,25D was to increase the
level of granulocytic differentiation (increased CD11b expression).
The situation was different in regard to expression of monocytic
marker CD14. For the cell lines in which ATRA up-regulated VDR
expression (KG1 and NB-4) combined treatment also up-regulated
CD14, when compared to single treatment. For the cell lines in
which ATRA down-regulated VDR expression it also down-
regulated CD14, when compared to 1,25D alone. These results
point to increased VDR expression shifts the differentiation option
from the granulocytic to the monocytic pathway.
3.2. Effects of 1,25D and ATRA on regulation of CYP24A1 expression
The CYP24A1 gene encodes the enzyme 24-hydroxylase of
1,25D, which is the key enzyme in the degradation of 1,25D to
calcitroic acid. It is well documented that CYP24A1 is the most
strongly regulated of all the 1,25D-target genes [29], thus 1,25D-
dependent up-regulation of CYP24A1 conﬁrms that VDR protein isFig. 3. Regulation of CYP24A1 transcription in response to 1,25D or/and ATRA in AML c
KG1 (A), NB-4 (B), HL60 (C), MOLM-13 (D), NOMO-1 (E) and U937 (F) cells were exposed to
measured by Real-time PCR. The bar charts show the mean values (SEM) of the fold cha
(p < 0.05) from those obtained for respective control cells are marked with asterisks, an
respective 1,25D-treated samples are marked by ¥.expressed and active in cells. For the AML cell lines that responded
well to 1,25D, the expression of CYP24A1 was slowly, but
signiﬁcantly, up-regulated up to a thousand-fold, as compared
to untreated cells [26]. As shown in Fig. 3(A) and 3C, measurements
of CYP24A1 levels reﬂected ATRA-driven changes in VDR expression
and activation levels in KG1 and in HL60 cells. Similarly in MOLM-
13 (Fig. 3D) and U937 (Fig. 3F) cells ATRA-driven changes in VDR
expression were further reﬂected in expression of CYP24A1. In the
case of NB-4 (Fig. 3(B)) and in NOMO-1 cells (Fig. 3E) 1,25D-
induced CYP24A1 expression was not altered to a signiﬁcant degree
by ATRA. The data presented in Fig. 3 show that ATRA alone does
not inﬂuence CYP24A1 expression. Moreover, ATRA-induced
changes to CYP24A1 expression conﬁrmed that increased VDR
mRNA levels lead to increased translation of VDR protein, which is
activated by ligand. It is noteworthy that the observed 1,25D-
induced CYP24A1 expression in HL60 cells is one order of
magnitude higher than in MOLM-13 and NOMO-1 cells, two
orders of magnitude higher than in NB-4 cells and three to four
orders of magnitude higher than in KG1 and U937 cells.
3.3. Transcriptional variants of VDR in HL60 and KG1 cells as identiﬁed
by 50-RACE
For these studies we chose to use the HL60 and KG1 cell lines as
the most sensitive and least sensitive to 1,25D, respectively. We
considered that variable regulation of VDR gene in these cell lines
might result from the usage of different VDR promoters. Therefore,
we decided to identify the promoter regions that regulate VDR
transcription in un-stimulated and ATRA-stimulated HL60 and
KG1 cells, and examined the transcript variants occurring in those
cells. We used the 50-RACE method to identify 50 portions of the
VDR transcripts—upstream of the VDR exon 2. The results of our
experiments are presented in Fig. 1(B) and aligned to the published
sequence. We found that in both un-stimulated and ATRA-
stimulated HL60 cells, VDR transcripts originated from exon 1a
which was spliced to exon 2 either directly or through exon 1c. The
same transcript variants were the most frequently detectedells.
 10 nM 1,25D or/and 1 mM ATRA and after 96 h the expression of CYP24A1 mRNA was
nges in mRNA levels relative to GAPDH mRNA levels. Values that differ signiﬁcantly
d values that differ signiﬁcantly (p < 0.05) in 1,25D + ATRA treated samples versus
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addition, we observed that KG1 cells express a more diverse set of
VDR transcripts than HL60 cells. In un-stimulated KG1 cells, weFig. 4. Regulation of VDR transcription variants in response to RAR selective and non-s
Expression and regulation of VDR 1a and VDR 1d transcriptional variants was examined in
or to 1 mM ATRA and after 96 h the levels of VDR 1a and VDR 1d mRNA were measured rela
controls are marked with asterisks.
The inﬂuence of non-selective and selective RAR agonists towards VDR 1a expression was
100 nM RAR agonists and after 96 h the levels of VDR 1a mRNA were measured relative to 
of the fold changes. Results that differ signiﬁcantly (p < 0.05) from the respective cont
The inﬂuence of non-selective and selective RAR agonists towards VDR 1g expression wa
agonists and after 96 h the levels of VDR 1 g mRNA were measured relative to GAPDH mRN
changes. Results that differ signiﬁcantly (p < 0.05) from the respective control are mardetected transcript variants originating from exon 1d and, from a
so-far-unidentiﬁed exon, depicted in Fig. 1(B) as exon 1g, and
localized downstream of exon 1d. In contrast to HL60, in KG1 cellselective agonists in HL60 and KG1 cells.
 HL60 (A) and KG1 (B) cells by Real-time PCR. The cells were exposed to 10 nM 1,25D
tive to GAPDH mRNA levels. Results that differ signiﬁcantly (p < 0.01) from respective
 examined in HL60 (C) and in KG1 (D) cells. The cells were exposed to 10 nM 1,25D or
GAPDH mRNA levels by Real-time PCR. The bar charts show the mean values (SEM)
rol are marked with asterisks.
s examined in KG1 (E) cells. The cells were exposed to 10 nM 1,25D or 100 nM RAR
A levels by Real-time PCR. The bar charts show the mean values (SEM) of the fold
ked with asterisks.
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from exon 1a or 1g. Aside from the differences between HL60 and
KG1 cells, the majority of transcripts expressed in both cell types,
regardless of the presence or absence of ATRA, originated from
exons controlled by the 1a promoter. This strongly suggests a
predominant role of the 1a promoter in regulating VDR expression
in these cells.
3.4. Regulation of VDR variants in response to ATRA and to selective
RAR agonists
The most frequent transcriptional variants in HL60 and
KG1 cells are the ones originating in exon 1a and exon 1d. Hence,
we constructed variant-speciﬁc primers in order to quantify ATRA-
provoked changes in the expression of these transcripts. Our
experiments have shown that only the transcript which originates
from exon 1a (VDR 1a) is regulated in response to 1 mM ATRA. This
transcript was signiﬁcantly down-regulated in HL60 cells
(Fig. 4(A)), and signiﬁcantly up-regulated in KG1 cells (Fig. 4B).
ATRA is a non-selective agonist of RARa, b and g. We used selective
agonists of RAR isoforms to determine the isoform responsible for
regulating the VDR transcript that originates from exon 1a. The
agents used at a concentration of 100 nM were AGN191183 (pan-
RAR agonist), AGN195183 (RARa agonist), tazarotene (RARbg
agonist), AGN205327 (RARg agonist) and BMS453 (RARb agonist)
and their structures and classiﬁcation are given in Supplementary
Table 2. As shown in Fig. 4(C) (HL60) and 4D (KG1), the pan-RAR
agonist, the selective RARa agonist and the mixed RARbg agonist
(tazarotene) signiﬁcantly regulated transcription of VDR 1a. Among
the transcript variants of VDR gene in KG1 cells we identiﬁed rare
transcripts, which originated from a newly discovered exon 1 g. We
tested whether these transcripts are also regulated by the RAR
agonists. In HL60 cells such regulation did not occur (not shown),
but VDR1 g transcript appeared to be regulated by RAR agonists in
KG1 cells (Fig. 4(E)). The pattern of regulation of VDR1 g and VDR1aFig. 5. RAR isoforms and VDR in HL60 and KG1 cells.
(A) Long (1935/ + 71) and short (464/ + 71) 1a promoter regions were cloned upstream
together with the control Renilla luciferase vector. The cells were then left untreated or t
cells. The bar charts show mean values (SEM) of Fireﬂy/Renilla luciferase units, and the
asterisk.
(B) The expression RARA,RARB and RARG was examined in untreated HL60 and KG1 cells b
values of the absolute expression levels (SEM). Results that differ signiﬁcantly (p < 0.
The levels of RARa (C) and VDR (D) proteins were determined in the cytosol and nuclei of 
exposed to 10 nM 1,25D for 24 h. The cytosolic (C) and nuclear (N) extracts were separated
anti-RARa, anti-VDR and anti-actin. The OD ratio of each receptor band was calculated ve
the blots.in KG1 cells is similar, which suggests that the promoter region
used to regulate both transcripts is the same. The data presented in
Fig. 4 indicate that the most important isoform of RAR involved in
VDR transcription is RARa. Signiﬁcant up-regulation in KG1 cells,
and signiﬁcant down-regulation in HL60 cells of VDR1a by
tazarotene suggests that RARb and g also have limited regulatory
effects, which is further supported by the observation that
combination treatment using RARb and RARg agonists mimics
the effect of tazarotene (not shown here).
3.5. Reporter assays in HL60 cells treated with ATRA
In order to determine whether the promoter of exon 1a
responds directly to ATRA stimulation, two reporter vectors were
constructed that contained different portions of the 1a promoter
regions: 1935/+71 (1a long) and 464/+71 (1a short) relative to
the start site of the 1a transcript variant. Transient transfection
efﬁcacy was too low in KG1, therefore the activities of the promoter
regions could only be tested in HL60 cells. Fireﬂy luciferase
activities were normalized to the Renilla luciferase activities of the
internal control vector transfected at the same time. The
normalized luciferase activities in the cells treated with 1 mM
ATRA for 96 h were compared to the respective untreated controls.
When Fireﬂy luciferase gene was under the control of 1a short
promoter region, no effects of ATRA were observed, but when the
1a long promoter was used luciferase activity was signiﬁcantly
down-regulated by ATRA treatment, in keeping with the regulation
of the VDR 1a variant in response to ATRA in HL60 cells (Fig. 5(A)).
3.6. Expression of VDR in the absence of RARa
Having shown that RARa ligated by its selective agonist
regulates transcription of the VDR gene in HL60 and KG1 cells, we
investigated the role of un-ligated RARa in these cells. Our
experiments had shown that constitutive expression of RARA of the Fireﬂy luciferase gene in the pGL3 Basic vector and transfected into HL60 cells
reated with 1 mM ATRA for 96 h and the luciferase activities were measured in these
 value that differs signiﬁcantly (p = 0.02) from the respective control is marked with
y Real-time PCR relative to GAPDH expression levels. The bar charts show the mean
01) in KG1 cells from HL60 cells are marked with asterisks.
HL60 and KG1 cells by Western blots. In order to visualize VDR protein, the cells were
 by SDS-PAGE, transferred to PVDF membranes and the proteins were revealed using
rsus the OD of the respective actin band and the means (SEM) are presented below
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Also the protein level of RARa in the nucleus was higher in
KG1 than in HL60 cells (Fig. 5(C)). Even though RARB mRNA levels
were high in both cell lines, RARb protein was undetectable in our
experiments. RARG expression was low in both cell lines, and RARg
protein was not detectable.
Therefore, we silenced the expression of RARA in KG1 cells. The
gene silencing was performed using RARA shRNA lentiviral
particles and the scrambled shRNA lentiviral particles as a control.Fig. 6. VDR in KG1 cells post-silenced expression of RARa.
KG1 cells were transformed using lentivirus containing either scrambled shRNA (KG1-CT
and VDR mRNA(C) in both cell lines were measured by Real-time PCR. The bar charts sh
mRNA levels. The values that in KG1-RARa() cells are signiﬁcantly (p < 0.01) differen
The levels of RARa (B) and VDR (D) proteins were determined in the cytosol and nuclei of 
the cells were exposed to 10 nM 1,25D for 24 h. The cytosolic (C) and nuclear (N) extracts w
revealed using anti-RARa, anti-VDR and anti-actin. Anti-Lamin C antibody was used to sh
versus the OD of a respective actin band and the means (SEM) are presented below 
(E) The expression of VDR mRNA was tested by Real-time PCR in KG1-CTR and KG1-RARa
mean values (SEM) of the VDR mRNA levels relative to GAPDH mRNA levels.
The untreated KG1-CTR samples were calculated as 1. The values that differ signiﬁcantly 
The values that differ signiﬁcantly (p < 0.05) from RARa-agonist treated cells are markAfter selecting transduced cells in puromycin containing medium,
we obtained two KG1 sublines; KG1-RARa(), from the use of
RARA shRNA, and KG1-CTR, from the use of scrambled shRNA. The
level of gene silencing was examined by Real-time PCR (Fig. 6(A))
and by Western blotting (Fig. 6B, top panel). Whilst RARa silencing
was not complete in KG1-RARa() cells the level was signiﬁcant at
around 85%. Next, we investigated whether the loss of RARa
inﬂuenced the basal level of transcription of VDR. The level of VDR
mRNA in KG1-RARa() cells was observed to be almost 5 timesR) or RARA speciﬁc shRNA (KG1-RARa()). The expression levels of RARA mRNA (A)
ow the mean values (SEM) of the fold changes in mRNA levels relative to GAPDH
t than in KG1-CTR cells are marked by asterisks.
KG1-CTR and KG1-RARa() cells by Western blots. In order to visualize VDR protein,
ere separated by SDS-PAGE, transferred to PVDF membranes and the proteins were
ow the purity of cell fractionation. The OD ratio of each receptor band was calculated
the blots.
() cells exposed to 100 nM selective RAR agonists for 96 h. The bar charts show the
(p < 0.05) in treated cells from the respective untreated control are marked by hash.
ed by diamond.
A. Marchwicka et al. / Journal of Steroid Biochemistry & Molecular Biology 159 (2016) 121–130 129higher than in the cells transfected with the control plasmid
(Fig. 6(C)). This level was less than the basal level of VDR mRNA in
HL60 cells, but more than the level in wild-type KG1 cells. In order
to conﬁrm that increased expression of VDR gene in KG1-RARa()
cells resulted in the translation of functional VDR protein, we
measured VDR protein levels in both sublines. It has been
documented earlier that VDR protein is stabilized by 1,25D, and
that a high level of VDR in the nucleus can be seen only after
addition of 1,25D to AML cells (presented in Fig. 5(D)) [30]. Thus,
we exposed KG1-CTR cells and KG1-RARa() cells to 10 nM 1,25D
for 24 h, or left untreated. As presented in Fig. 6(D), VDR protein
level was observed to be higher in nuclear fractions from KG1-
RARa() cells as compared to KG1-CTR cells, especially after
exposure to 1,25D.
We analyzed the inﬂuence of the selective RAR agonists on VDR
expression levels in both KG1 sublines. KG1-CTR cells were
similarly responsive to wild-type KG1 cells, while KG1-RARa()
had lost responsiveness to RAR agonists. The selective RARa
agonist induced a signiﬁcantly higher VDR expression in KG1-CTR
cells than any other agonist. The mixed RARbg agonist (tazar-
otene) induced signiﬁcant up-regulation of VDR, but to a much
lower extent than when the RARa agonist was used alone
(Fig. 6(E)).
4. Discussion
The fact that retinoids regulate the expression of the VDR gene
in bone and mammary cells is well described, and this effect is
known to be cell-type dependent [12,15]. Also, it is well established
that RARa acts as transcriptional repressor when un-ligated [19],
and after binding its physiological agonist ATRA then functions to
activate transcription [20]. However, precise details are lacking of
the molecular events that occur in AML cell lines.
KG1 cells have a high basal level of expression of RARA gene, a
high constitutive content of RARa protein and a low level of VDR
protein. Here, we have shown that un-ligated RARa represses
expression of the VDR gene in KG1 cells. When KG1 cells were
treated with either a selective or non-selective ligand to activate
RARa, expression of VDR was observed to be up-regulated. A
similar effect was obtained by silencing RARA gene expression. We
interpret these ﬁndings to suggest that RARa protein devoid of
ligand acts as transcriptional repressor to the VDR gene in these
cells. Accordingly, HL60 cells have a low constitutive level of
expression of RARA, a low level of RARa protein, and their basal
level of expression of VDR is high. Treatment of these cells with a
RARa ligand resulted in down-regulation of VDR expression, and
the reason for this effect remains to be investigated. As to a higher
level of RARa in KG1 cells as compared to HL60 cells; KG1 are
viewed as more primitive than the promyeloid cell line HL60 and a
change in the level of expression of RARA as cells age develop-
mentally may be the underlying reason.
The transcriptional regulation of VDR gene is very complex
because of the use of several alternative promoter regions in the
large regulatory region encompassing 65 kb upstream of the
coding region (exons 2–9) [13]. In our studies we have identiﬁed
transcripts starting from exon 1a within KG1 and HL60 cells. These
are the transcripts that are regulated when cells are treated either
with ATRA or a RARa speciﬁc agonist. From our studies, we have
also identiﬁed a new non-coding exon, here termed 1 g, which
either can be used as a transcript start, or alternatively spliced into
the transcripts starting from exon 1a.
A more complete understanding of the mechanism whereby
expression of the VDR gene is regulated in response to retinoids is
confounded by the fact that a classical RARE does not exist within
the entire VDR promoter region. However, it should be remem-
bered that the location of RAREs is highly variable, and ranges from10,145 bases upstream to 8141 bases downstream of the 50 end of
known transcription start site [31], so the regulatory element does
not need to be located in close proximity to the VDR gene. It has
also been documented that RAREs are often located in intronic
regions [32]. Moreover, recent studies have revealed a high level of
diversity in the topology and spacing of RAREs. Classical RAREs are
composed of two direct repeats of a core hexameric nucleotide
sequence, spaced by 1, 2 or 5 random nucleotides (named DR1,
DR2 and DR5). New data have revealed that RAREs do not have to
be spaced at all (DR0), they can be spaced by 8 nucleotides (DR8) or
composed of the inverted repeats (IR) [33]. To circumvent the, as
yet, lack of a RARE involved in VDR regulation, it has been
suggested that retinoids regulate VDR transcription in a secondary
manner, by using cis-regulatory elements which cooperate with
the promoter [13]. Until now, these elements have been localized
in the vicinity of exon 1c, either downstream [13] or upstream [15],
depending on the cell type. Here we have shown for AML cells that
a putative cis-regulatory element, which is used by RARs, is located
in the promoter region of exon 1a, between nucleotides 1935 and
464 relative to the transcriptional start site of 1a. The attempts to
specify the exact location of the regulatory element are underway
in our laboratories.
As mentioned above, whether ATRA treatment of AML cell lines
leads to up- or down-regulation of expression of VDR depends on
the cell line tested. It is important to bear in mind that several
kinase signal transduction pathways are rapidly activated when
cells are treated with ATRA. [34]. This, in turn, might inﬂuence the
phosphorylation status of particular RAR isoforms [35]. Kinase-
mediated signaling is also likely to lead to the activation of other
transcription factors to change the transcriptional cell landscape.
Differences between the AML cell lines as to their signaling and/or
transcriptional landscapes may underlie the opposite effects on
expression of VDR when different AML cell lines are treated with
ATRA. Such considerations are also important to what happens to
VDR expression when patients’ AML cells are treated with ATRA as
these cells often have mutations affecting signal transduction
pathways. The KG1 cell line alludes to the importance of kinase
signaling as these cells harbor a fusion protein kinase FOP2-FGFR1,
arising from the FGFR1 Oncogene Partner 2 (FGFR1OP2)—
FGFR1 fusion gene, which is constitutively active [36].
The use of 1,25D in combination with ATRA may beneﬁt some
but not all AML patients. The addition of ATRA to 1,25D is likely to
beneﬁt patients if this leads to up-regulation rather than down-
regulation of VDR, as in the later case VDR protein is reduced to the
detriment of combination differentiation therapy. As shown here,
insight to the nature and mechanisms of ATRA-provoked changes
to the level of VDR expression is important to consideration of the
clinical use of ATRA with 1,25D.
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